CDC Guideline for Prescribing Opioids for Chronic Pain

Deborah Hastings, MD, MS
Senior Medical Advisor, Division of Unintentional Injury Prevention

Alaska Opioid Policy Taskforce
July 8, 2016
Chronic pain and prescription opioids

- 11% of Americans experience daily (chronic) pain
- Opioids frequently prescribed for chronic pain
- Primary care providers commonly treat chronic, non-cancer pain
  - account for ~50% of opioid pain medications dispensed
  - report concern about opioids and insufficient training
The amount of opioids prescribed has QUADRUPLED from 1999-2014, but the pain that Americans report remains UNCHANGED.
Since 1999, there have been more than 165,000 deaths from overdose related to prescription opioids.
Need for Opioid Prescribing Guidelines

• Most recent national guidelines are several years old and do not incorporate the most recent evidence

• Need for clear, consistent recommendations
Purpose, use, and primary audience

- Recommendations for the prescribing of opioid pain medications
  - for patients 18 and older
  - in outpatient, primary care settings
  - in treatment for chronic pain
- Not intended for use in active cancer treatment, palliative care, or end-of-life care
- Primary Audience: Primary Care Providers
  - Family Practice, Internal medicine
  - Physicians, nurse practitioners, physician assistants
Guideline development process

ANALYZE
- Systematic Literature Review
- CDC Draft Recommendations
- Core Expert Group Consultation
- CDC Draft Guideline

CONSULT
- Core Expert & Stakeholder Review
- Federal Partner Review
- Peer Review
- Constituent Input (Webinar)

COMMENT
- CDC Revised Guideline
- FRN Public Comment
- Federal Advisory Committee Review
- Publication of Guideline (March 15, 2016)

REVIEW
GRADE evidence types

• Evidence types:
  – Type 1: Randomized controlled trials (RCTs); overwhelming observational studies
  – Type 2: RCTs (limitations); strong observational
  – Type 3: RCTs (notable limitations); observational
  – Type 4: RCTs (major limitations); observational (notable limitations) clinical experience
GRADE recommendation categories

• Recommendation categories:
  – Category A: applies to all patients; most patients should receive recommended course of action
  – Category B: individual decision making required; providers help patients arrive at decision consistent with values/preferences and clinical situation
CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016
Deborah Dowell, Tamara Haegerich, and Roger Chou

CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016

Published online March 15, 2016
Clinical evidence summary

• No long-term (> 1 year) outcomes in pain/function; most placebo-controlled trials ≤ 6 weeks
• Opioid dependence in primary care: 3%-26%
• Dose-dependent association with risk of overdose/harms
• Initiation with ER/LA opioids increased risk of overdose
• Methadone associated with higher mortality risk
• No differences in pain/function with dose escalation
• Risk prediction instruments have insufficient accuracy
• Increased likelihood of long-term use when opioids used for acute pain
Contextual evidence summary

- Effective nonpharmacologic therapies: exercise, cognitive behavioral therapy (CBT)
- Effective nonopioid medications: acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, antidepressants
- Opioid-related overdose risk is dose-dependent
- Providers lack confidence in ability to prescribe safely and are concerned about opioid use disorder
- Patients are ambivalent about risks/benefits and associate opioids with addiction
Relationship of prescribed opioid dose (MME) and overdose

Odds Ratio or Hazard Ratio for Overdose Relative to 1 to <20 MME

- Bohnert 2011 (fatal overdose)
- Dunn 2010 (overdose)
- Gomes 2011 (fatal overdose)
- Zedler 2014 (overdose)
Longer durations and higher doses of opioid treatment associated with opioid use disorder

Organization of recommendations

• The 12 recommendations are grouped into three conceptual areas:
  – Determining when to initiate or continue opioids for chronic pain
  – Opioid selection, dosage, duration, follow-up, and discontinuation
  – Assessing risk and addressing harms of opioid use
Determine when to initiate or continue opioids for chronic pain
Opioids not first-line or routine therapy for chronic pain

- Nonpharmacologic therapy and nonopioid pharmacologic therapy are preferred for chronic pain.
- Clinicians should consider opioid therapy only if expected benefits for both pain and function are anticipated to outweigh risks to the patient.
- If opioids are used, they should be combined with nonpharmacologic therapy and nonopioid pharmacologic therapy, as appropriate.

(Recommendation category: A; Evidence type: 3)
Establish and measure progress toward goals

• Before starting opioid therapy for chronic pain, clinicians should establish treatment goals with all patients, including realistic goals for pain and function, and should consider how therapy will be discontinued if benefits do not outweigh risks.

• Clinicians should continue opioid therapy only if there is clinically meaningful improvement in pain and function that outweighs risks to patient safety.

(Recommendation category: A; Evidence type: 4)
Discuss benefits and risks with patients

• Before starting and periodically during opioid therapy, clinicians should discuss with patients known risks and realistic benefits of opioid therapy and patient and clinician responsibilities for managing therapy.

(Recommendation category: A; Evidence type: 3)
Opioid selection, dosage, duration, follow-up, and discontinuation
Use immediate-release opioids when starting

- When starting opioid therapy for chronic pain, clinicians should prescribe immediate-release opioids instead of extended-release/long-acting (ER/LA) opioids.

(Recommendation category: A; Evidence type: 4)

Additional cautions for
- Methadone
- Transdermal fentanyl
- Immediate-release opioids combined with ER/LA opioids
Use caution at any dose and avoid increasing to high dosages

- When opioids are started, clinicians should prescribe the lowest effective dosage.
- Clinicians should use caution when prescribing opioids at any dosage, should carefully reassess evidence of individual benefits and risks when increasing dosage to ≥50 morphine milligram equivalents (MME)/day, and should avoid increasing dosage to ≥90 MME/day or carefully justify a decision to titrate dosage to ≥90 MME/day.

(Recommendation category: A; Evidence type: 3)
Prescribe no more than needed

- Long-term opioid use often begins with treatment of acute pain. When opioids are used for acute pain, clinicians should prescribe the lowest effective dose of immediate-release opioids and should prescribe no greater quantity than needed for the expected duration of pain severe enough to require opioids.
- 3 days or less will often be sufficient; more than 7 days will rarely be needed.

(Recommendation category: A; Evidence type: 4)
Offer a taper if opioids cause harm or are not helping

- Clinicians should evaluate benefits and harms with patients within 1 to 4 weeks of starting opioid therapy for chronic pain or of dose escalation.
- Clinicians should evaluate benefits and harms of continued therapy with patients every 3 months or more frequently.
- If benefits do not outweigh harms of continued opioid therapy, clinicians should optimize other therapies and work with patients to taper opioids to lower dosages or to taper and discontinue opioids.

(Recommendation category: A; Evidence type: 4)
Assessing risk and addressing harms of opioid use
Evaluate and address risks for opioid-related harms

• Before starting and periodically during continuation of opioid therapy, clinicians should evaluate risk factors for opioid-related harms.

• Clinicians should incorporate into the management plan strategies to mitigate risk, including considering offering naloxone when factors that increase risk for opioid overdose, such as history of overdose, history of substance use disorder, higher opioid dosages (≥50 MME/day), or concurrent benzodiazepine use, are present.

(Recommendation category: A; Evidence type: 4)
Check PDMP for high dosages and dangerous combinations

- Clinicians should review the patient’s history of controlled substance prescriptions using state PDMP data to determine whether the patient is receiving opioid dosages or dangerous combinations that put him/her at high risk for overdose.
- Clinicians should review PDMP data when starting opioid therapy for chronic pain and periodically during opioid therapy for chronic pain, ranging from every prescription to every 3 months.

(Recommendation category: A; Evidence type: 4)
Test urine for prescribed opioids and other drugs

• When prescribing opioids for chronic pain, clinicians should use urine drug testing before starting opioid therapy and consider urine drug testing at least annually to assess for prescribed medications as well as other controlled prescription drugs and illicit drugs.

(Recommendation category: B; Evidence type: 4)
Avoid concurrent opioid and benzodiazepine prescribing

- Clinicians should avoid prescribing opioid pain medication and benzodiazepines concurrently whenever possible.

(Recommendation category: A; Evidence type: 3)
Treat patients for opioid use disorder (OUD) if needed

- Clinicians should offer or arrange evidence-based treatment (usually medication-assisted treatment with buprenorphine or methadone in combination with behavioral therapies) for patients with opioid use disorder.

(Recommendation category: A; Evidence type: 2)
Implementation Activities
CDC guideline implementation

1. Translation and communication

2. Clinical training

3. Health system implementation

4. Insurer/pharmacy benefit manager implementation
Resources

- Fact sheets
  - New Opioid Prescribing Guideline
  - Assessing Benefits and Harms of Opioid Therapy
  - Prescription Drug Monitoring Programs
  - Calculating Total Daily Dose of Opioids for Safer Prescribing
  - Pregnancy and Opioid Pain Medications
**PRESCRIPTION DRUG MONITORING PROGRAMS (PDMPs)**

**WHAT IS A PDMP?**

A PDMP is a statewide electronic database that tracks all controlled substance prescriptions. Authorized users can access prescription data such as medications dispensed and doses.

PDMPs improve patient safety by allowing clinicians to:

- Identify patients who are obtaining opioids from multiple providers.
- Calculate the total amount of opioids prescribed per day (in MME/day).
- Identify patients who are being prescribed other substances that may increase risk of opioids—such as benzodiazepines.

**WHAT SHOULD I CONSIDER WHEN PRESCRIBING OPIOIDS?**

- **High Dosage**
  - Talk to your patient about the risks for respiratory depression and overdose. Consider offering to taper opioids as well as prescribing naloxone for patients taking 50 MME/day or more.

- **Multiple Providers**
  - Counsel your patient and coordinate care with their other prescribers to improve safety and discuss the need to obtain opioids from a single provider. Check the PDMP regularly and consider tapering or discontinuation of opioids if pattern continues.

- **Drug Interactions**
  - Whenever possible, avoid prescribing opioids and benzodiazepines concurrently. Communicate with other prescribers to prioritize patient goals and weigh risks of concurrent opioid and benzodiazepine use.

**WHEN SHOULD I CHECK THE PDMP?**

State requirements vary, but CDC recommends checking at least once every 3 months and consider checking prior to every opioid prescription.

**WHAT SHOULD I DO IF I FIND INFORMATION ABOUT A PATIENT IN THE PDMP THAT CONCERNS ME?**

Patients should not be dismissed from care based on PDMP information. Use the opportunity to provide potentially life-saving information and interventions.

1. Confirm that the information in the PDMP is correct.
   - Check for potential data entry errors, use of a nickname or maiden name, or possible identity theft to obtain prescriptions.

2. Assess for possible misuse or abuse.
   - Offer or arrange evidence-based treatment (usually medication-assisted treatment with buprenorphine or methadone in combination with behavioral therapies) for patients who meet criteria for opioid use disorder. If you suspect diversion, urine drug testing can assist in determining whether opioids can be discontinued without causing withdrawal.

3. Discuss any areas of concern with your patient and emphasize your interest in their safety.
Checklist for prescribing opioids for chronic pain
Coming soon

- Mobile “app” with MME calculator
- Videos
- Brochures and pocket guides
- Online training for providers
- Additional materials, such as matte articles, blogs, infographics
Training

• Training modules for clinicians
  – Online modules
  – CME credits
• Guideline-concordant education
  – Medical schools
  – Nursing schools
  – Pharmacy schools
Health systems interventions

• Clinical quality improvement technical package
  – Help health systems develop guideline-concordant quality improvement processes
  – Facilitate adoption and use of recommendations
• Updated clinical decision supports for EHRs
• Coordinated Care Plan for Safer Practice
  – Guidance for health system operations
  – Content closely aligned to the CDC Guideline
  – Focus: reducing risk if already on chronic opioid therapy
Five things insurers can do to address the opioid epidemic

1. Cover non-pharmacologic therapies like exercise and cognitive behavioral therapy

2. Make it easier to prescribe non-opioid pain medications

3. Reimburse patient counseling, care coordination, and checking PDMP

4. Promote more judicious use of high dosages of opioids using drug utilization review and prior authorization

5. Remove barriers to evidence-based treatment of opioid use disorder (e.g., eliminate lifetime limits on buprenorphine)
For more information, contact CDC
1-800-CDC-INFO (232-4636)

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.